View Older Stories

May 27, 2026 06:45AM H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)

May 13, 2026 08:50AM Legend Biotech Corp. (LEGN) PT Raised to $64; RBC Capital: 'We see opportunity for share appreciation'

May 12, 2026 07:30AM Legend Biotech (LEGN) Misses Q1 EPS by 16c

Apr 21, 2026 06:36AM H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)

Apr 21, 2026 06:31AM Raymond James on Legend Biotech Corp. (LEGN): 'the dataset suggests very strong efficacy with room for improvement on safety'

Apr 20, 2026 10:51AM RBC on Legend Biotech Corp. (LEGN): 'We Think Shares Remain Undervalued'

Apr 20, 2026 06:35AM H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)

Apr 15, 2026 07:18AM H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)

Mar 11, 2026 08:46AM Legend Biotech Corp. (LEGN) PT Lowered to $62 at RBC Capital; 'Shares Should Rebound in 2026'

Mar 10, 2026 05:41PM Legend Biotech Corp. (LEGN) PT Lowered to $49 at Morgan Stanley

Mar 10, 2026 03:53PM Raymond James Reiterates Outperform Rating on Legend Biotech Corp. (LEGN) following Q4

Mar 10, 2026 12:10PM Truist Securities Reiterates Buy Rating on Legend Biotech Corp. (LEGN): "infer from comments that Raritan's full manufacturing slot capacity approved"

Mar 10, 2026 12:01PM Jefferies Reiterates Buy Rating on Legend Biotech Corp. (LEGN)

Mar 10, 2026 08:49AM Legend Biotech (LEGN) Reports In-Line Q4 EPS

Mar 6, 2026 03:42PM Raymond James Reiterates Outperform Rating on Legend Biotech Corp. (LEGN): "pressure on Legend shares... overdone"

Feb 23, 2026 09:31AM Raymond James on Legend Biotech Corp. (LEGN): 'Arcellx Takeout Indicates Legend is Hugely Undervalued'

Feb 12, 2026 02:37AM Rothschild Redburn Downgrades Legend Biotech Corp. (LEGN) to Neutral

Jan 22, 2026 06:40AM Legend Biotech Corp. (LEGN) PT Lowered to $50 at H.C. Wainwright

Jan 22, 2026 12:58AM TD Cowen Downgrades Legend Biotech Corp. (LEGN) to Hold

Jan 20, 2026 12:01PM Raymond James Reiterates Outperform Rating on Legend Biotech Corp. (LEGN) After FDA Draft Guidance

Jan 15, 2026 07:11AM Deutsche Bank on Legend Biotech Corp. (LEGN): 'Most incremental, in our view, LEGN will share first patient data for its in-vivo CAR T program by YE26'

Dec 21, 2025 04:00AM Biotechnology: Here are Piper Sandler's Top Picks and Focus Names for 2026

Dec 17, 2025 07:23AM Legend Biotech (LEGN) Reiterated at Overweight by Cantor Fitzgerald

Dec 9, 2025 12:38PM RBC Capital Defends Legend (LEGN) For Second Day in a Row As Stock Continues to Push Lower

Dec 8, 2025 07:49AM RBC Capital on Legend Biotech Corp. (LEGN): 'We Would Be Buyers'

Dec 8, 2025 02:54AM Legend Biotech reports 50-month survival data for CARVYKTI in myeloma

Nov 19, 2025 06:45AM Breakthrough Properties partners with Eli Lilly for Philadelphia lab space

Oct 17, 2025 06:45AM Legend Biotech Corp. (LEGN) PT Lowered to $60 at H.C. Wainwright

Oct 12, 2025 03:00PM Biotech stocks: Q3 earnings preview

Oct 7, 2025 06:10AM Cantor Fitzgerald Starts Legend Biotech Corp. (LEGN) at Overweight

Sep 12, 2025 06:29AM RBC Capital Reiterates Outperform Rating on Legend Biotech Corp. (LEGN)

Sep 11, 2025 08:18AM RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'

Sep 10, 2025 09:16AM RBC Capital on Biotech: 'Who Wins and Who Loses If RFK, Jr. Goes'

Aug 27, 2025 06:08AM Cantor Fitzgerald Assumes Legend Biotech Corp. (LEGN) at Overweight

Aug 12, 2025 10:20AM Legend Biotech Corp. (LEGN) PT Raised to $77 at RBC Capital on Growth Potential

Aug 11, 2025 12:16PM Legend Biotech (LEGN) Tops Q2 EPS by 15c

Jul 17, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)

Jul 17, 2025 05:35AM Goldman Sachs Reiterates Buy Rating on Legend Biotech Corp. (LEGN)

Jul 16, 2025 12:38PM JNJ results have positive read-through for Legend Biotech (LEGN) - Barclays

Jul 16, 2025 07:35AM Legend Biotech (LEGN) Announces Preliminary Sales for CARVYKTI

Jul 3, 2025 09:24AM Legend Biotech Corp. (LEGN) PT Lowered to $54 at UBS

Jul 2, 2025 06:38AM H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)

Jul 1, 2025 06:00AM BMO lists 3 top biotech ideas for H2

Jun 3, 2025 10:45AM Legend Biotech (LEGN) Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting

Jun 2, 2025 07:03AM RBC Capital: 'Legend Biotech Corp. (LEGN) Still Undervalued'

Jun 2, 2025 05:08AM BMO Capital Reiterates Outperform Rating on Legend Biotech Corp. (LEGN)

May 22, 2025 05:25PM Legend Biotech (LEGN) announces new data evaluating CARVYKTI

May 16, 2025 10:32AM RBC Capital on Legend Biotech Corp. (LEGN): 'We See A Compelling Valuation'

May 14, 2025 01:56AM Legend Biotech (LEGN) Misses Q1 EPS by 6c

May 13, 2025 04:38PM TD Cowen Reiterates Buy Rating on Legend Biotech Corp. (LEGN), PT $62, 'We Like The Profile At These Levels'

View Older Stories